6aq6

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "6aq6" [edit=sysop:move=sysop])
Current revision (14:22, 4 October 2023) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 6aq6 is ON HOLD until Paper Publication
+
==X-ray crystal structure of Erythrina crista-galli lectin in complex with N-acetyllactosamine==
 +
<StructureSection load='6aq6' size='340' side='right'caption='[[6aq6]], [[Resolution|resolution]] 1.90&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[6aq6]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Erythrina_crista-galli Erythrina crista-galli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AQ6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6AQ6 FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.903&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CA:CALCIUM+ION'>CA</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GAL:BETA-D-GALACTOSE'>GAL</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=MN:MANGANESE+(II)+ION'>MN</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=XYP:BETA-D-XYLOPYRANOSE'>XYP</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6aq6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6aq6 OCA], [https://pdbe.org/6aq6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6aq6 RCSB], [https://www.ebi.ac.uk/pdbsum/6aq6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6aq6 ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/Q6YD91_ERYCG Q6YD91_ERYCG]
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Protein-carbohydrate interactions are significant in a wide range of biological processes, disruption of which has been implicated in many different diseases. The capability of glycan-binding proteins (GBPs) to specifically bind to the corresponding glycans allows GBPs to be utilized in glycan biomarker detection or conversely to serve as targets for therapeutic intervention. However, understanding the structural origins of GBP specificity has proven to be challenging due to their typically low binding affinities (mM) and their potential to display broad or complex specificities. Here we perform molecular dynamics (MD) simulations and post-MD energy analyses with the Poisson-Boltzmann and generalized Born solvent models (MM-PB/GBSA) of the Erythrina cristagalli lectin (ECL) with its known ligands, and with new cocrystal structures reported herein. While each MM-PB/GBSA parametrization resulted in different estimates of the desolvation free energy, general trends emerged that permit us to define GBP binding preferences in terms of ligand substructure specificity. Additionally, we have further decomposed the theoretical interaction energies into contributions made between chemically relevant functional groups. Based on these contributions, the functional groups in each ligand can be assembled into a pharmacophore comprised of groups that are either critical for binding, or enhance binding, or are noninteracting. It is revealed that the pharmacophore for ECL consists of the galactopyranose (Gal) ring atoms along with C6 and the O3 and O4 hydroxyl groups. This approach provides a convenient method for identifying and quantifying the glycan pharmacophore and provides a novel method for interpreting glycan specificity that is independent of residue-level glycan nomenclature. A pharmacophore approach to defining specificity is readily transferable to molecular design software and, therefore, may be particularly useful in designing therapeutics (glycomimetics) that target GBPs.
-
Authors: Gerlits, O., Woods, R.J.
+
Defining the Specificity of Carbohydrate-Protein Interactions by Quantifying Functional Group Contributions.,Sood A, Gerlits OO, Ji Y, Bovin NV, Coates L, Woods RJ J Chem Inf Model. 2018 Sep 24;58(9):1889-1901. doi: 10.1021/acs.jcim.8b00120., Epub 2018 Aug 22. PMID:30086239<ref>PMID:30086239</ref>
-
Description: X-ray crystal structure of Erythrina crista-galli lectin in complex with N-acetyllactosamine
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Gerlits, O]]
+
<div class="pdbe-citations 6aq6" style="background-color:#fffaf0;"></div>
-
[[Category: Woods, R.J]]
+
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Erythrina crista-galli]]
 +
[[Category: Large Structures]]
 +
[[Category: Gerlits O]]
 +
[[Category: Woods RJ]]

Current revision

X-ray crystal structure of Erythrina crista-galli lectin in complex with N-acetyllactosamine

PDB ID 6aq6

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools